Clinical Course of COVID-19 in a Thalassemia Major Patient who Underwent Haematopoietic Stem Cell Transplantation

Creative Commons License

Hamidi A. A. , Ulu Y., Aktaş H.

Bezmiâlem Science, cilt.9, ss.91-93, 2021 (Diğer Kurumların Hakemli Dergileri)

  • Cilt numarası: 9 Konu: 1
  • Basım Tarihi: 2021
  • Doi Numarası: 10.14235/bas.galenos.2020.4916
  • Dergi Adı: Bezmiâlem Science
  • Sayfa Sayıları: ss.91-93


We herein reported the course of Coronavirus diasease-19 (COVID-19) in a 21-year-old patient with thalassemia majo rdisease. The patient who underwent haematopoietic stem cell transplantation in 2013 and developed alloimmunization, presented with high fever and weakness. His parents have been recently diagnosed with COVID-19. COVID-19 diagnosis was confirmed by real time-polymerase chain reaction (RT-PCR) method in the nasopharyngeal swab sample of the patient while his thorax computed tomography was not found in favor of pneumonia. The patient was treated with hydroxychloroquine 2x200mg and Favipravir 3x600mg. The temperature fell with in three days. The clinical condition of the patient improved rapidly. On the 20th day, he did not have any symptom with a recovery of anemia and lymphopenia, but the RT-PCR result was stil positive. In this case report, we wanted to point out that the course of the COVID-19 is unexpectedly mild in such a patient with thalassemia major.